Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors’ reply

da Silva IP, Ahmed T, Reijers ILM, Warner AB, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Zimmer L, Trojaniello C, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Menzies AM, Long GV. Lancet Oncol. 22(8):e343-e344.

Read Full Paper